Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
Holding ADCT?
Track your performance easily
ADCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $6.04
Previous Close$3.06
Volume105.30K
Average Volume (3M)366.93K
Market Cap
$279.08M
Enterprise Value$108.14M
Total Cash (Recent Filing)$300.10M
Total Debt (Recent Filing)$123.01M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 05, 2024EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.56
Shares Outstanding96,647,450
10 Day Avg. Volume284,172
30 Day Avg. Volume366,927
Standard Deviation0.28
R-Squared0.08
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-2.25
Price to Sales (P/S)8.04
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit1.61
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$8.33Price Target Upside178.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
ADC Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination of glofitamab plus Zynlonta could be a true game changer in diffuse large B-cell lymphoma (DLBCL).
Financial PerformanceADC Therapeutics achieved commercial brand profitability with revenues of $34.9 million year-to-date.
Safety And EfficacyThe ongoing LOTIS-7 study in relapsed/refractory B-cell Non-Hodgkin Lymphoma has cleared all three dose levels without any discontinuations due to adverse events in heavily pre-treated patients.
Bears Say
EarningsZYNLONTA's quarterly sales were $17.0M, which is lower than the previous sales of $17.8M and below the forecasted $19.0M.
Financial PerformanceADCT reported results with a net loss of $36.5 million.
Market And Regulatory RisksRisks include inability to obtain timely approval for ADCT-402 in DLBCL, slower than anticipated market uptake, clinical setbacks, failures with other pipeline candidates, and possible medium- to long-term dilution risk.
---
Ownership Overview
32.15% Insiders
1.42% Mutual Funds
0.20% Other Institutional Investors
62.45% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADCT FAQ
What was ADC Therapeutics Ltd’s price range in the past 12 months?
ADC Therapeutics Ltd lowest stock price was $0.36 and its highest was $6.04 in the past 12 months.
What is ADC Therapeutics Ltd’s market cap?
Currently, no data Available
When is ADC Therapeutics Ltd’s upcoming earnings report date?
ADC Therapeutics Ltd’s upcoming earnings report date is Nov 05, 2024 which is in 6 days.
How were ADC Therapeutics Ltd’s earnings last quarter?
ADC Therapeutics Ltd released its earnings results on Aug 06, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.457 by $0.077.
Is ADC Therapeutics Ltd overvalued?
According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued.
Does ADC Therapeutics Ltd pay dividends?
ADC Therapeutics Ltd does not currently pay dividends.
What is ADC Therapeutics Ltd’s EPS estimate?
ADC Therapeutics Ltd’s EPS estimate is -$0.38.
How many shares outstanding does ADC Therapeutics Ltd have?
ADC Therapeutics Ltd has 96,687,706 shares outstanding.
What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?
ADC Therapeutics Ltd reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.457. Following the earnings report the stock price went up 1.742%.
Which hedge fund is a major shareholder of ADC Therapeutics Ltd?
Among the largest hedge funds holding ADC Therapeutics Ltd’s share is Grosvenor Holdings, L.L.C.. It holds ADC Therapeutics Ltd’s shares valued at 5M.
---
ADC Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (178.22% Upside)
$8.33 (178.22% Upside)
Blogger Sentiment
Bullish
ADCT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
337.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-26.71%
Trailing 12-Months
Company Description
ADC Therapeutics Ltd
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
---
ADCT Company Deck
---
ADCT Earnings Call
Q2 2024
0:00 / 0:00
---
ADCT Stock 12 Month Forecast
Average Price Target
$8.33
▲(178.22% Upside)
Technical Analysis
Best Analysts Covering ADCT
1 Year
1 Year Success Rate
8/18 ratings generated profit
1 Year Average Return
+24.19%
reiterated a buy rating 26 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +24.19% per trade.
---